The Role of Telemedicine in the Treatment of Cognitive and Psychological Disorders in Parkinson’s Disease: An Overview

Latella, Dèsiréè; Maresca, Giuseppa; Formica, Caterina; Sorbera, Chiara; Bringandì, Amelia; Lorenzo, Giuseppe Di; Quartarone, Angelo; Marıno, Silvia

doi:10.3390/brainsci13030499

Cited by 4 publications

(4 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are several types of subspecialty care via telemedicine. As PD is a multidomain disorder, swallowing therapy [ 15 ], speech therapy, rehabilitation [ 16 ], cognitive therapy, and psychological therapy [ 17 ] are helpful for patients, and several researches on this has been conducted with favorable results. In our survey, approximately 50% of respondents had intention to receive treatment for speech and swallowing problems, cognitive and psychiatric problems and rehabilitation by telemedicine.…”

Section: Discussionmentioning

confidence: 99%

A Survey of Perspectives on Telemedicine for Patients With Parkinson’s Disease

Joo,

Yun,

Kim

et al. 2024

JMD

View full text Add to dashboard Cite

Objective Parkinson’s disease (PD) patients often find it difficult to visit hospitals because of motor symptoms, distance to the hospital, or the absence of caregivers. Telemedicine is one way to solve this problem.Methods We surveyed 554 PD patients from eight university hospitals in Korea. The questionnaire consisted of the clinical characteristics of the participants, possible teleconferencing methods, and preferences for telemedicine.Results A total of 385 patients (70%) expressed interest in receiving telemedicine. Among them, 174 preferred telemedicine whereas 211 preferred in-person visits. The longer the duration of disease, and the longer the time required to visit the hospital, the more patients were interested in receiving telemedicine.Conclusion This is the first study on PD patients’ preferences regarding telemedicine in Korea. Although the majority of patients with PD have a positive view of telemedicine, their interest in receiving telemedicine depends on their different circumstances.

show abstract

Section: Discussionmentioning

confidence: 99%

A Survey of Perspectives on Telemedicine for Patients With Parkinson’s Disease

Joo,

Yun,

Kim

et al. 2024

JMD

View full text Add to dashboard Cite

show abstract

“…Psychological support helps a patient to feel independent and reinforced with stabilized emotions [67][68][69]. Such kind of mental support helps in slowing down the pace of neuronal degeneration.…”

Section: Alternative Therapiesmentioning

confidence: 99%

Customized treatment for Parkinson’s disease: extending lifespan and improving symptoms

Indu,

Dimri

2024

Egypt J Neurol Psychiatry Neurosurg

View full text Add to dashboard Cite

Background Parkinson's disease (PD) is the second most prevalent neurodegenerative ailment affecting aged people. Several motor and non-motor symptoms appearing with this disease are linked to reduction in dopamine levels. Parkinson’s disease manifested by a wide range of symptoms, including gait instability, voice impairments, bradykinesia, hypomimia, tremors, and cognitive dysfunctions, where the concern is its steady global progression. Therefore, by evaluating the stage-specific retention and transition thresholds, the suggested work attempts to detect the progression of PD. Similarly, the assessment of the annual rate of deterioration of symptoms aids in assessing the influence of medications on four stages and six prime symptoms. Results During the 9-year period following clinical diagnosis, a symptomatic deterioration of 34.995% is observed in untreated patients compared to treated patients. Furthermore, the experimental analysis illustrates that medicines assist in regulating only bradykinesia, tremors, hypomimia, and speech impairment, which lasts for 4.8 years on average. A saturation period is also identified during the moderate phase, where the computed average depreciation in the Unified Parkinson’s Disease Rating Scale (UPDRS) is the least. Similarly, from stages 1 to 4, medicines might improve stage retention by 4.44, 3.5, 2.72, and 1.6 years, respectively. It demonstrates that, despite transient advantages and adverse effects, medications also have an optimistic impact on PD patients. Conclusions Here, we show that medication can extend the lifespan of PD patients up to 12 years cumulatively. Furthermore, the proposed work suggests that stagewise alternative remedies for improving quality of life, boosting the benefits of medicines, and eliminating their side effects. These include counselling, diet changes, yoga asanas, herbal medicines, bio-cleansing and other therapies. The current work does not consider the temporary transition among stages; nonetheless, further investigation regarding PD could open avenues for more worthy treatments with fewer side effects.

show abstract

“…Telemedicine allows for the remote provision of healthcare services for patients with neurodegenerative diseases, including PD, thereby overcoming geographical barriers and allowing for better access to specialized medical care [ 81 , 82 ]. Motor fluctuations and lack of sufficient social support may limit the ability of PD patients to attend psychotherapy sessions in-person [ 35 ].…”

Section: Non-pharmacological Treatments For Depression In Pdmentioning

confidence: 99%

Pharmacological and Non-Pharmacological Treatments for Depression in Parkinson’s Disease: An Updated Review

et al. 2023

View full text Add to dashboard Cite

Depression represents one of the most common non-motor disorders in Parkinson’s disease (PD) and it has been related to worse life quality, higher levels of disability, and cognitive impairment, thereby majorly affecting not only the patients but also their caregivers. Available pharmacological therapeutic options for depression in PD mainly include selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, and tricyclic antidepressants; meanwhile, agents acting on dopaminergic pathways used for motor symptoms, such as levodopa, dopaminergic agonists, and monoamine oxidase B (MAO-B) inhibitors, may also provide beneficial antidepressant effects. Recently, there is a growing interest in non-pharmacological interventions, including cognitive behavioral therapy; physical exercise, including dance and mind–body exercises, such as yoga, tai chi, and qigong; acupuncture; therapeutic massage; music therapy; active therapy; repetitive transcranial magnetic stimulation (rTMS); and electroconvulsive therapy (ECT) for refractory cases. However, the optimal treatment approach for PD depression is uncertain, its management may be challenging, and definite guidelines are also lacking. It is still unclear which of these interventions is the most appropriate and for which PD stage under which circumstances. Herein, we aim to provide an updated comprehensive review of both pharmacological and non-pharmacological treatments for depression in PD, focusing on recent clinical trials, systematic reviews, and meta-analyses. Finally, we discuss the pharmacological agents that are currently under investigation at a clinical level, as well as future approaches based on the pathophysiological mechanisms underlying the onset of depression in PD.

show abstract

The Role of Telemedicine in the Treatment of Cognitive and Psychological Disorders in Parkinson’s Disease: An Overview

Cited by 4 publications

References 76 publications

A Survey of Perspectives on Telemedicine for Patients With Parkinson’s Disease

A Survey of Perspectives on Telemedicine for Patients With Parkinson’s Disease

Customized treatment for Parkinson’s disease: extending lifespan and improving symptoms

Pharmacological and Non-Pharmacological Treatments for Depression in Parkinson’s Disease: An Updated Review

Contact Info

Product

Resources

About